Erratum: Is standardised 18F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? (European Journal of Nuclear Medicine and Molecular Imaging (2006) 33 (389) DOI: 10.1007/s00259-005-1953-2);Is standardised 18F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 3, 2006, Pages 263-269

  Eschmann, S M ^a   Friedel, G ^a   Paulsen, F ^a   Reimold, M ^a   Hehr, T ^a   Budach, W ^a   Scheiderbauer, J ^a   Machulla, H J ^a   Dittmann, H ^a   Vonthein, R ^a   Bares, R ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

FDG; Non small cell lung cancer; Positron emission tomography; Standardised uptake value

Indexed keywords

CARBOPLATIN; FLUORODEOXYGLUCOSE F 18; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACCUMULATION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; RECURRENT CANCER; REFERENCE VALUE; STANDARD; TREATMENT PLANNING; TUMOR VOLUME;

EID: 33644967941     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1984-8     Document Type: Erratum

References (19)

1. Saunders CA, Dussek JE, O'Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999;67:790-7
2. Schrevens L, Lorent N, Dooms C, Vansteenkiste J. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. The Oncologist 2004;9(6):633-43
3. 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 1997;10:2529-34
4. 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994;344:1265-6
5. Pieterman RM, Van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small cell lung cancer with positron emission tomography. N Engl J Med 2000;343:254-61
6. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001;42:1596-604
7. 18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer 2003;39:151-7
8. Schmucking M, Baum RP, Griesinger F, Presselt N, Bonnet R, Przetak C, et al. Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. Recent Results Cancer Res 2003;162:195-202
9. Eschmann SM, Friedel G, Paulsen F, Budach W, Harer-Mouline C, Dohmen BM, et al. FDG-PET for staging in patients with advanced non-small cell lung cancer (NSCLC) scheduled for neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging 2002;29:804-8
10. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002;43:39-45
11. Ahuja V, Coleman RE, Herndon J, Patz EF. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma. Cancer 1998;83:918-24
12. 18F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 2002;23:865-70
13. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109(1):120-9
14. Komaki R, Cox JD, Hartz AJ, Byhardt RW, Perez-Tamayo C, Clowry L, et al. Characteristics of long-term survivors after treatment for inoperable carcinoma of the lung. Am J Clin Oncol 1985;8(5):362-70
15. Higashi K, Ueda Y, Yagishita M, Arisaka Y, Sakurai A, Oguchi M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 2000;41:85-92
16. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837-44
17. Higashi K, Ueda Y, Ayabe K, Sakurai A, Seki H, Nambu Y, et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathologic features. Nucl Med Commun 2000;21:707-14
18. 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. J Clin Oncol 1999;17:3201-6
19. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995;36:1836-9